File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Real-Life Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir in Chronic Hepatitis C Patients in Hong Kong

TitleReal-Life Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir in Chronic Hepatitis C Patients in Hong Kong
Authors
Issue Date2017
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal of Gastroenterology and Hepatology, 2017, v. 32 n. 6, p. 1230-1233 How to Cite?
AbstractBACKGROUND AND AIM: In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12-24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong. METHODS: We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program. RESULTS: Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty-five (85%) patients received 12-week treatment and six patients received 24-week treatment; 26 (63%) patients received ribavirin combination. Thirty-nine (95%; 95% confidence interval 88.5-100%) patients had undetectable HCV RNA at 12-week post-treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation. CONCLUSIONS: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong. © 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/237765
ISSN
2017 Impact Factor: 3.483
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, HLY-
dc.contributor.authorTsang, OTY-
dc.contributor.authorHui, YT-
dc.contributor.authorFung, JYY-
dc.contributor.authorLui, GCY-
dc.contributor.authorLai, CL-
dc.contributor.authorWong, GLH-
dc.contributor.authorChan, KH-
dc.contributor.authorBut, YKD-
dc.contributor.authorLai, MS-
dc.contributor.authorLao, WC-
dc.contributor.authorChan, CKM-
dc.contributor.authorLam, YS-
dc.contributor.authorSeto, WKW-
dc.contributor.authorLi, C-
dc.contributor.authorYuen, RMF-
dc.contributor.authorWong, VWS-
dc.date.accessioned2017-01-20T02:28:14Z-
dc.date.available2017-01-20T02:28:14Z-
dc.date.issued2017-
dc.identifier.citationJournal of Gastroenterology and Hepatology, 2017, v. 32 n. 6, p. 1230-1233-
dc.identifier.issn0815-9319-
dc.identifier.urihttp://hdl.handle.net/10722/237765-
dc.description.abstractBACKGROUND AND AIM: In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12-24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong. METHODS: We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program. RESULTS: Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty-five (85%) patients received 12-week treatment and six patients received 24-week treatment; 26 (63%) patients received ribavirin combination. Thirty-nine (95%; 95% confidence interval 88.5-100%) patients had undetectable HCV RNA at 12-week post-treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation. CONCLUSIONS: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong. © 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH-
dc.relation.ispartofJournal of Gastroenterology and Hepatology-
dc.titleReal-Life Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir in Chronic Hepatitis C Patients in Hong Kong-
dc.typeArticle-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.emailBut, YKD: drdbut@hku.hk-
dc.identifier.emailSeto, WKW: wkseto2@hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.doi10.1111/jgh.13663-
dc.identifier.hkuros270981-
dc.identifier.volume32-
dc.identifier.issue6-
dc.identifier.spage1230-
dc.identifier.epage1233-
dc.identifier.isiWOS:000402296800018-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats